Ligand Pharmaceuticals LGND Total debt

Total debt at other companies

Royalty PharmaRPRX

$8.96B+11.7%

Roivant SciencesROIV

$107.15M+7.5%

Relay Therapeutics, Inc.RLAY

$30.66M-10.3%

Ionis PharmaceuticalsIONS

$262.48M-67.0%

Innoviva, Inc.INVA

$269.66M-40.2%

Rigel PharmaceuticalsRIGL

$68.36M+5,079%

FAQ

What is Ligand Pharmaceuticals's total debt?

Ligand Pharmaceuticals (LGND) reported total debt of $1.13B in Q2 2026.

How has Ligand Pharmaceuticals's total debt changed year-over-year?

Ligand Pharmaceuticals's total debt increased by 19604.9% year-over-year, from $5.74M to $1.13B.

What is the long-term trend for Ligand Pharmaceuticals's total debt?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total debt has grown at a -23.8% compound annual growth rate (CAGR), from $20.83M to $5.35M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.